Express Press Release Distribution

Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel

EPR Archived News

Archived News 2012
~ April
~ March
~ February
~ January

Archived News 2011
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2010
Archived News 2009
Archived News 2008
Archived News 2007
Archived News 2006
Archived News 2005
Archived News 2004

 

Sanofi-Aventis to Present at GTCbio`s 4th Stem Cell Research and Therapeutics- April 17-18, Boston

Released on: January 23, 2008, 3:54 pm

Press Release Author: GTCbio

Industry: Pharmaceuticals

Press Release Summary: Dr. Christophe Labie, Group Leader of the Molecular
Neurobiology Group at Sanofi-Aventis will give a presentation entitled “Stimulation
of Brain Neurogenesis: A Way to Replace Neuron Loss in Diseased or Injured Brain” at
GTCbio’s 4th Stem Cell Research & Therapeutics on April 17-18, 2008 in Boston, MA.


Press Release Body: Dr. Christophe Labie, Group Leader of the Molecular Neurobiology
Group at Sanofi-Aventis will give a presentation entitled “Stimulation of Brain
Neurogenesis: A Way to Replace Neuron Loss in Diseased or Injured Brain” at GTCbio’s
4th Stem Cell Research & Therapeutics on April 17-18, 2008 in Boston, MA.

Regeneration-based therapy is an emerging area in modern medicine, as is evidenced
by numerous publications over the last decade. Published studies provide strong
evidence that neural stem cells or progenitor cells (herein referred to as NSCs)
persist and are widely distributed throughout the adult nervous system. In the
injured or diseased CNS, NSCs self replicate, migrate to damaged areas, and attempt
to repair damage by differentiating into neurons, astrocytes, and/or mature myelin
forming oligodendrocytes. One focus of the Sanofi-Aventis CNS department is to
identify pharmacological compounds that favor brain repair by enhancing
physiological natural repair processes. More specifically, the increase of neuronal
replacement by compounds stimulating endogenous neurogenesis, such as xaliproden,
will be presented.

Besides Dr. Labie’s presentation, the conference also features presentations from
other leading organizations such as Beckman Research Institute, FDA, Genzyme, Merck,
MIT, Pfizer, Sangamo BioSciences, Sanofi Aventis, University of Van Amsterdam,
Whitehouse Institute, and many more. The full agenda is available online at
www.gtcbio.com.

GTCbio’s 4th Stem Cell Research & Therapeutics will cover topics as Stem Cell
Biology, Adult Stem Cells, Embryonic Stem Cells, Differentiation of Stem Cells,
Epigenomics & Reprogramming of Stem Cells, Regenerative Medicine & Therapeutics,
Stem Cell Imaging, Regulatory Aspects & Funding Opportunities, Cancer Stem Cells,
and Stem Cell Applications in Drug Discovery.

For more information including a detailed agenda, exhibitor opportunities and
registration information visit http://gtcbio.com/userAgenda.aspx?id=120


ABOUT GTCbio

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.

Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com


Web Site: http://www.gtcbio.com

Contact Details: GTCbio
434 W Foothill Blvd.
Monrovia, CA 91016

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •